Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Cutaneous lymphoproliferative disorders research, and T-cell and Retrovirus Studies.
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas
Hepatosplenic T-cell lymphoma: a rare but challenging entity
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States
A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States
Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
A phase <scp>II</scp> study of cyclophosphamide, etoposide, vincristine and prednisone ( <scp>CEOP</scp> ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( <scp>PTCL</scp> ): final results from the T‐ cell consortium trial
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
Non-Hodgkin’s Lymphomas, Version 1.2013
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Non-Hodgkin’s Lymphomas, Version 3.2012
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas